RELATING TO INSURANCE -- PHARMACY BENEFIT MANAGERS ACT
S3060 creates a new chapter in Rhode Island insurance law titled the “Pharmacy Benefit Managers Act.” It requires any pharmacy benefit manager (PBM) operating in the state to obtain a certificate of authority from the director of the Department of Business Regulation before acting as, offering to act as, or holding itself out as a PBM. The bill defines PBM-related terms broadly and sets out a licensing framework that includes application materials, financial disclosures, business plans, ownership information, network and pricing practices, and other information the director may require.
The bill also establishes ongoing reporting and compliance obligations. PBMs would have to file annual reports on rebates, discounts, fees, manufacturer payments, and how those amounts are passed through or retained, along with detailed information about rebate contracts and drug-level pricing arrangements. The director would be authorized to examine PBMs, require additional reports, investigate inquiries, impose civil penalties for noncompliance, and suspend or revoke certificates for specified misconduct. The bill further provides for confidentiality of certain submitted information, creates a health insurance market integrity fund for penalty receipts, and directs the department to adopt implementing regulations.
If enacted, S3060 would add a new regulatory licensing and oversight regime for PBMs under Title 27 of the Rhode Island General Laws. It would give the Department of Business Regulation authority to certify PBMs, review their ownership and financial condition, monitor rebate and pricing practices, and enforce compliance through restitution, civil penalties, suspension, and revocation. The bill would also affect insurers, pharmacies, covered individuals, and PBM subcontractors by making PBMs responsible for a broad range of conduct and by requiring disclosure and reporting related to prescription drug benefit management.
Based on the bill text and available context, the overall sentiment appears supportive of stronger oversight of PBMs and more transparency in prescription drug pricing and rebate practices. The bill’s structure suggests a policy goal of increasing accountability, limiting anti-competitive or deceptive conduct, and giving state regulators more direct control over PBM operations. No committee transcript or recorded votes were provided, so there is no documented opposition or floor debate to indicate broader legislative sentiment beyond the bill’s stated regulatory intent.
The main points of contention likely center on the breadth of the reporting requirements, the level of state oversight, and the potential compliance burden on PBMs and their affiliated entities. The bill requires detailed disclosure of rebate contracts, retained amounts, pricing models, and business practices, which PBMs may view as commercially sensitive or administratively burdensome, even though the bill treats much of the information as confidential. Another possible issue is the director’s broad discretion to set application standards, require additional information, and determine when disclosure is in the public interest. No specific objections from legislators, insurers, pharmacies, or PBMs are included in the provided materials.